top of page
Milestones
Expansion & GMP Compliance
Expansion into a 50,000 sq. ft. manufacturing facility in Delhi, designed in accordance with Schedule M guidelines. Achieved GMP approval and initiated marketing operations India.
2000
The Beginning
The journey began with a focus on pharmaceutical trading, establishing a strong foundation in market understanding and distribution.
1991
International Expansion & WHO-GMP Facility
Strengthened global ambitions with establishment of a WHO-GMP certified manufacturing unit in Baddi, Himachal Pradesh, spanning over 100,000 sq. ft.
2007
Transition into Manufacturing
A strategic shift from trading to manufacturing marked the beginning of in-house production capabilities, with the establishment of a quality-focused facility.
1997
First Export Milestone
Successfully executed the first international shipment to Africa, marking the beginning of Maxtar Biogenics’ export journey.
2008
Global Presence Expansion
Strengthened international presence across Africa and Asia, with additional regulatory approvals from authorities in Ivory Coast and Malawi.
2017
Growing Global Footprint
Expanded presence across international markets including Africa, Southeast Asia, and CIS. Secured registrations and approvals from key authorities such as NAFDAC, Philippines FDA, Ghana, and Vietnam.
2012
Exports to 25+ Countries
Expanded export operations to over 25 countries, reinforcing Maxtar Biogenics’ position as a reliable global pharmaceutical partner.
2019
2016
Backward Integration – Packaging Unit
Established an in-house packaging unit to strengthen supply chain efficiency and ensure quality control across printed materials including cartons, foils, and corrugated packaging.
Recognition as Star Export House
Honored with the prestigious Star Export House recognition by the Government of India, reflecting consistent export performance and global trust.
2021
Expansion into Latin America
Entered the Latin American market and established a local presence to strengthen regional operations and partnerships.
2022
2026
EU-GMP Upgrade – Tablets & Capsules Facility
Initiated reconstruction and upgradation of tablets and capsules manufacturing unit to align with EU-GMP standards, reinforcing commitment to markets and quality benchmarks.
2027 Planned
Injectable Facility Development (EU-GMP)
Strategic plan to establish a injectable manufacturing unit designed in compliance with EU-GMP standards, expanding capabilities into sterile formulations and high-value dosage segments.
bottom of page